Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma - PubMed
3 hours ago
- #central nervous system lymphoma
- #CD3xCD20 bispecific antibodies
- #clinical outcomes
- The study evaluates clinical outcomes of CD3xCD20 bispecific antibodies in lymphoma patients with central nervous system involvement.
- Research conflicts include funding from Incyte and GSK, and consulting for Genentech, Kite, and BMS, while other authors declare no conflicts.
- References cite real-world data on therapies like lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma with CNS involvement.